A randomised controlled trial investigating efficacy of a novel toothpaste containing calcium silicate and sodium phosphate in dentine hypersensitivity pain reduction compared to a fluoride control toothpaste.


Journal

Journal of dentistry
ISSN: 1879-176X
Titre abrégé: J Dent
Pays: England
ID NLM: 0354422

Informations de publication

Date de publication:
07 2020
Historique:
received: 20 01 2020
revised: 11 03 2020
accepted: 13 03 2020
pubmed: 5 6 2020
medline: 12 1 2021
entrez: 5 6 2020
Statut: ppublish

Résumé

To compare a calcium silicate and sodium phosphate toothpaste (CSSP) with a fluoride negative control toothpaste for dentine hypersensitivity (DH) pain reduction after 14, 28 and 29 days. This was a double blind, parallel study in 247 healthy adults with DH (Schiff score >2, tactile 10-20 g) in 2 teeth in different quadrants of the mouth. After acclimatisation, participants were randomised to CSSP or control toothpaste. After measuring baseline sensitivity products were applied twice-daily by toothbrushing, and once daily massaging into the sensitive teeth. Sensitivity was assessed following airblast (Schiff and VAS) and tactile (Yeaple probe) stimuli at baseline, 14 and 28 days, and at 29 days, 12 h after last product application. Participants completed a quality of life questionnaire at each study visit up to day 28. After 14, 28 and 29 days the CSSP group had significantly lower Schiff, lower VAS and higher Yeaple probe scores compared to control (VAS at 14 days, p < 0.04; all other comparisons, p < 0.001). Quality of life scores improved in both groups, but no significant differences between groups were observed. The CSSP toothpaste was more effective than the fluoride control toothpaste at reducing DH pain with benefit persisting 12 h following application. This novel calcium silicate and sodium phosphate toothpaste (CSSP) toothpaste is an effective twice-daily treatment when brushed on the teeth for dentine hypersensitivity sufferers compared to brushing with a conventional fluoride paste. Twice-daily brushing provides a sustained effect for long-lasting pain relief from dentine hypersensitivity.

Identifiants

pubmed: 32497553
pii: S0300-5712(20)30059-2
doi: 10.1016/j.jdent.2020.103320
pii:
doi:

Substances chimiques

Calcium Compounds 0
Dentin Desensitizing Agents 0
Phosphates 0
Silicates 0
Toothpastes 0
Sodium Fluoride 8ZYQ1474W7
Arginine 94ZLA3W45F
Calcium Carbonate H0G9379FGK
Fluorides Q80VPU408O
calcium silicate S4255P4G5M
sodium phosphate SE337SVY37

Banques de données

ClinicalTrials.gov
['NCT03244618']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103320

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Joon Seong (J)

Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: J.Seong@bristol.ac.uk.

Robert G Newcombe (RG)

Institute of Primary Care & Public Health, Cardiff University, Cardiff, CF10 3AT, UK. Electronic address: newcombe@cardiff.ac.uk.

Jane R Matheson (JR)

Unilever Oral Care, Quarry Road East, Bebington, CH63 3JU, UK. Electronic address: Jane.Matheson@unilever.com.

Lynnette Weddell (L)

Unilever Oral Care, Quarry Road East, Bebington, CH63 3JU, UK. Electronic address: Lynnette.Weddell@unilever.com.

Mark Edwards (M)

Unilever Oral Care, Unilever House, 100 Victoria Embankment, London, EC4Y 0DY, UK. Electronic address: Mark.Edwards@unilever.com.

Nicola X West (NX)

Clinical Trials Group, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK. Electronic address: n.x.west@bristol.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH